Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-4-29 in Relapsed/Refractory Multiple Myeloma
NCT04861480Phase 1Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD70 CAR-T cells in multiple myeloma (MM), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after C-4-29 infusion at 28 days and Maximum tolerated dose of C-4-29 cells at 28 days. Status: unknown.
02
Drugs
CD70 CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04861480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861480.